TY - JOUR
T1 - Oxidative status in different settings and with different methodological approaches compared by Receiver Operating Characteristic curve analysis
AU - Cighetti, Giuliana
AU - Bamonti, Fabrizia
AU - Aman, Caroline S.
AU - Gregori, Dario
AU - De Giuseppe, Rachele
AU - Novembrino, Cristina
AU - de Liso, Federica
AU - Maiavacca, Rita
AU - Paroni, Rita
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives: To test the performance of different analytical approaches in highlighting the occurrence of deregulated redox status in various physio-pathological situations. Design and methods: 35 light and 61 heavy smokers, 19 chronic renal failure, 59 kidney transplanted patients, and 87 healthy controls were retrospectively considered for the study.Serum oxidative stress and antioxidant status, assessed by spectrophotometric Reactive Oxygen Metabolites (d-ROMs) and Total Antioxidant Capacity (TAC) tests, respectively, were compared with plasma free (F-MDA) and total (T-MDA) malondialdehyde, both quantified by isotope-dilution-gas chromatography-mass spectrometry (ID-GC-MS). Sensitivity, specificity and cut-off points of T-MDA, F-MDA, d-ROMs and TAC were evaluated by both Receiver Operating Characteristic (ROC) analyses and area under the ROC curve (AUC). Results: Only T-MDA assay showed a clear absence of oxidative stress in controls and significant increase in all patients (AUC 1.00, sensitivity and specificity 100%). Accuracy was good for d-ROMs (AUC 0.87, sensitivity 72.8%, specificity 100%) and F-MDA (AUC 0.82, sensitivity 74.7%, specificity 83.9%), but not high enough for TAC to show in patients impaired antioxidant defense (AUC 0.66, sensitivity 52.0%, specificity 92.9%). Conclusions: This study reveals T-MDA as the best marker to detect oxidative stress, shows the ability of d-ROMs to identify modified oxidative status particularly in the presence of high damages, and evidences the poor TAC performance. d-ROMs and TAC assays could be useful for routine purposes; however, for an accurate clinical data evaluation, their comparison versus a "gold standard method" is required.
AB - Objectives: To test the performance of different analytical approaches in highlighting the occurrence of deregulated redox status in various physio-pathological situations. Design and methods: 35 light and 61 heavy smokers, 19 chronic renal failure, 59 kidney transplanted patients, and 87 healthy controls were retrospectively considered for the study.Serum oxidative stress and antioxidant status, assessed by spectrophotometric Reactive Oxygen Metabolites (d-ROMs) and Total Antioxidant Capacity (TAC) tests, respectively, were compared with plasma free (F-MDA) and total (T-MDA) malondialdehyde, both quantified by isotope-dilution-gas chromatography-mass spectrometry (ID-GC-MS). Sensitivity, specificity and cut-off points of T-MDA, F-MDA, d-ROMs and TAC were evaluated by both Receiver Operating Characteristic (ROC) analyses and area under the ROC curve (AUC). Results: Only T-MDA assay showed a clear absence of oxidative stress in controls and significant increase in all patients (AUC 1.00, sensitivity and specificity 100%). Accuracy was good for d-ROMs (AUC 0.87, sensitivity 72.8%, specificity 100%) and F-MDA (AUC 0.82, sensitivity 74.7%, specificity 83.9%), but not high enough for TAC to show in patients impaired antioxidant defense (AUC 0.66, sensitivity 52.0%, specificity 92.9%). Conclusions: This study reveals T-MDA as the best marker to detect oxidative stress, shows the ability of d-ROMs to identify modified oxidative status particularly in the presence of high damages, and evidences the poor TAC performance. d-ROMs and TAC assays could be useful for routine purposes; however, for an accurate clinical data evaluation, their comparison versus a "gold standard method" is required.
KW - Antioxidant status
KW - Isotope-dilution-gas chromatography-mass spectrometry
KW - Malondialdehyde
KW - Method comparison
KW - Oxidative stress
KW - ROC curve analysis
UR - http://www.scopus.com/inward/record.url?scp=84920276268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920276268&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2014.09.025
DO - 10.1016/j.clinbiochem.2014.09.025
M3 - Article
C2 - 25305628
AN - SCOPUS:84920276268
VL - 48
SP - 73
EP - 78
JO - Clinical Biochemistry
JF - Clinical Biochemistry
SN - 0009-9120
IS - 1-2
ER -